Pfizer, Celltrion say data backs switch to Remicade biosimilar
Pfizer and Celltrion Healthcare have unveiled new data showing that switching patients with Crohn’s disease from Remicade to biosimilar Inflectra showed comparable efficacy, safety and tolerability over a 24-week period.
Read More





